• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
RetailUnicorns

Walgreens Is Reportedly Taking Steps to Dump Theranos

Phil Wahba
By
Phil Wahba
Phil Wahba
Senior Writer
Phil Wahba
By
Phil Wahba
Phil Wahba
Senior Writer
February 29, 2016, 10:33 AM ET

Walgreens (WBA) is reportedly looking into ways to definitely end its relationship with troubled blood-testing start up Theranos.

According to the Financial Times, citing people familiar with the matter, Walgreens has asked lawyers to comb through its contract with Theranos to see if it can force the once high-flying Silicon Valley “unicorn” led by Elizabeth Holmes to close 40+plus blood-testing wellness centers it operates within Walgreens’ drugstores in Arizona (and one in California.) If successful, Walgreens’ move would be a devastating blow to Theranos, which operates all but one of its centers within the drugstore chain’s stores.

A representative for Walgreens declined to comment to Coins2Day, while a spokeswoman for Theranos did not immediately respond to a request for comment.

This latest report marks a continued deterioration between the two companies. A few weeks ago, Walgreens told Theranos to immediately stop sending any lab tests provided through Theranos Wellness Centers at Walgreens to its lab in Newark, Calif. For analysis. The day before, the U.S. Government’s Centers for Medicare & Medicaid Services (CMS) said Theranos’ deficient practices at the Newark lab posed “immediate jeopardy to patient health and safety.”

Walgreens, which operates an 8,000-drugstore chain, doesn’t see how Theranos can quickly fix its regulatory problems, prompting it to looking into simply ending the companies’ arrangement, which has proven to be a big PR headache for Walgreens, the FT report said. Recent reports in the Wall Street Journal have suggested that its blood-testing devices were flawed and had problems with accuracy.

At the same time, the FT reported that Theranos believes Walgreens has little legal basis for terminating the partnership because it has submitted an improvement plan to CMS among other steps.

About the Author
Phil Wahba
By Phil WahbaSenior Writer
LinkedIn iconTwitter icon

Phil Wahba is a senior writer at Coins2Day primarily focused on leadership coverage, with a prior focus on retail.

See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.